RxDoctor Payments Data

Peter Popovich

Optometrist · Dixon, ILNPI 1649629072

Payments from drug & device makers

$852in general payments, 2019–2025

Across 26 payments — averaging $32.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$462
  • Shire North American Group Inc$100
  • Coopervision Inc.$67
  • Sight Sciences, Inc.$65
  • Biotissue Holdings Inc.$41
  • Oyster Point Pharma, Inc.$34
  • plus $84 from 3 others

What the payments were for

  • Food & beverage$852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$852 in reported general payments places this provider in the 60th percentile of 2,257 optometrist providers in Illinois.

See all optometrist providers in Illinois

Medicare billing

Part B allowed, 2024
$45,769
Medicare patients
371
Services billed
977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine39$32,625
XiidraLifitegrast26$17,987
TafluprostTafluprost/Pf11$1,444
Dexamethasone Sodium Phosphate16$1,104
Latanoprost106$816
Doxycycline Hyclate15$458
Prednisolone Acetate13$414
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat23$337
Ketorolac Tromethamine18$324
Brimonidine Tartrate39$273
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha22$250
Ciprofloxacin Hcl18$181
ErythromycinErythromycin Base17$132
Dorzolamide Hcl11$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$31$32,62539 claims
Bausch & Lomb Americas Inc.Xiidra$19$17,98726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,257 optometrist providers in Illinois.

Other optometrist in Dixon

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →